Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
$2.26
+1.3%
$3.03
$1.84
$5.31
$77.35M1.63249,360 shs2.63 million shs
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$6.38
+0.5%
$6.07
$4.02
$15.10
$344.66M2.11.75 million shs926,633 shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$5.31
+1.1%
$5.24
$3.81
$29.30
$483.93M1.841.25 million shs907,164 shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$9.69
+1.1%
$10.24
$5.83
$26.25
$400.77MN/A217,038 shs165,539 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
0.00%-33.43%-36.10%-16.48%-52.55%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
0.00%+1.16%0.00%+30.74%-6.96%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.00%+6.71%+25.60%-40.81%-78.54%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
0.00%+4.24%+0.52%+21.27%+957,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
1.5776 of 5 stars
3.80.00.00.02.40.00.6
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
4.1459 of 5 stars
3.51.00.04.61.32.51.3
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
4.4213 of 5 stars
4.13.00.04.12.01.70.6
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.7806 of 5 stars
3.50.00.00.02.70.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
3.50
Strong Buy$14.33534.22% Upside
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
3.00
Buy$14.33124.66% Upside
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.13
Hold$14.38170.90% Upside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
3.00
Buy$36.67278.40% Upside

Current Analyst Ratings Breakdown

Latest ACHV, MYGN, ZBIO, and EBS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.00
5/16/2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/15/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.00
5/15/2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$35.00
5/8/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Peer Perform
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$18.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $8.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $7.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$22.00 ➝ $6.00
4/17/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
N/AN/AN/AN/A$0.61 per shareN/A
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$1.04B0.33$1.93 per share3.31$8.91 per share0.72
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$837.60M0.58$1.01 per share5.25$7.70 per share0.69
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$5M81.07N/AN/A$7.48 per share1.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
-$39.83M-$1.34N/AN/AN/AN/A-176.11%-103.32%8/12/2025 (Estimated)
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
-$190.60M-$2.71N/A3.08N/A-13.63%-0.52%-0.17%8/5/2025 (Estimated)
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$127.30M-$1.12N/AN/AN/A-12.20%-4.95%-3.39%8/5/2025 (Estimated)
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$156.99M-$3.55N/AN/AN/AN/AN/A8/21/2025 (Estimated)

Latest ACHV, MYGN, ZBIO, and EBS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.15-$0.80+$0.35-$0.80$5.00 million$10.00 million
5/13/2025Q1 2025
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
-$0.37-$0.37N/A-$0.37N/AN/A
5/7/2025Q1 2025
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$0.49$0.71+$0.22$1.19$218.50 million$222.20 million
5/6/2025Q1 2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$0.05-$0.03+$0.02N/A$200.37 million$195.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
N/AN/AN/AN/AN/A
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
N/AN/AN/AN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
N/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
0.85
3.51
3.51
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
1.20
6.32
3.51
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.08
1.90
1.71
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A
6.47
6.47

Institutional Ownership

CompanyInstitutional Ownership
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
33.52%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
78.40%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
99.02%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
3.00%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
3.20%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.10%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
16.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Achieve Life Sciences, Inc. stock logo
ACHV
Achieve Life Sciences
2034.69 million33.64 millionOptionable
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
2,42054.28 million52.54 millionOptionable
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2,70092.18 million90.24 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A41.83 million34.93 millionN/A

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Achieve Life Sciences stock logo

Achieve Life Sciences NASDAQ:ACHV

$2.26 +0.03 (+1.35%)
As of 04:00 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Emergent Biosolutions stock logo

Emergent Biosolutions NYSE:EBS

$6.38 +0.03 (+0.47%)
As of 03:58 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Myriad Genetics stock logo

Myriad Genetics NASDAQ:MYGN

$5.31 +0.06 (+1.14%)
As of 04:00 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$9.69 +0.11 (+1.15%)
As of 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.